Advances in treatment of chronic myelogenous leukemia new treatment options with tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 50, Issue SUPPL. 2, 2009, Pages 16-26

  Santos, Fabio P S ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Dasatinib; Imatinib; Nilotinib; Therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ALPHA INTERFERON; AP 24534; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CORTICOSTEROID; CYTARABINE; DANUSERTIB; DASATINIB; DCC 2036; DIURETIC AGENT; DP 2494; FINGOLIMOD; HOMOHARRINGTONINE; IMATINIB; KW 2449; NILOTINIB; OMACETAXINE MEPESUCCINATE; PANOBINOSTAT; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE INHIBITOR; SGX 393; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BILIRUBIN BLOOD LEVEL; BLEEDING TENDENCY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; ENZYME BLOOD LEVEL; FATIGUE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GENE; GENE MUTATION; GENETICS; HEADACHE; HEMATOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LOW DRUG DOSE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN DOMAIN; QT INTERVAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; T315I GENE; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 73849134744     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903383427     Document Type: Review

References (100)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
3. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1- positive chronic myeloid leukemia. Blood 2009;113:1619-1630.
4. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
5. Allan NC. Therapeutic options in chronic myeloid leukaemia. Blood Rev 1989;3:45-52.
6. Interferon a versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997;89:1616-1620.
7. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992;80:1352-1357.
8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
9. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653.
10. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI- 571). Cancer Res 2002;62:4236-4243.
11. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative. Cancer Res 1996;56: 100-104.
12. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947-4952.
13. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
14. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
15. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
17. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
18. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539. (Pubitemid 34534519)
19. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937. (Pubitemid 34525471)
20. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
21. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with acceleratedphase chronic myelogenous leukemia-comparison with historic experience. Cancer 2005;103:2099-2108.
22. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-a-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835-1840.
23. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98:2636-2642. (Pubitemid 37509527)
24. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112:76 (Abstract 186).
25. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029.
26. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659-1669.
27. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
28. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
29. Soverini S,Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronicmyeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-4109.
30. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-1773. (Pubitemid 44574988)
31. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphatebinding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-3475.
32. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-1018.
33. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
34. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-2249.
35. le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-323. (Pubitemid 38392356)
36. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
37. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499.
38. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028.
39. Ault P, Kantarjian HM, Bryan J, et al. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML). Blood 2008;112:(Abstract 4255).
40. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745.
41. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005;106:1133-1134; author reply 1134.
42. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704.
43. Wendel HG, de Stanchina E, Cepero E, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006;103:7444-7449.
44. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr- Abl is suppressed by kinase-defective Hck. J Biol Chem 2000;275:18581-18585.
45. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698.
46. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672-677.
47. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Ablindependent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227-34239.
48. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2- chloro-6-methyl- phenyl)- 2-(6-(4-(2-hydroxyethyl)-piperazin- 1-yl)- 2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
49. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinibresistant ABL mutants. Cancer Res 2006;66:5790-5797.
50. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
51. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
52. Lee FY, Lombardo L, Camuso A, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005;46:159 (Abstract 675).
53. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-481.
54. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541. (Pubitemid 43882349)
55. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22: 1200-1206.
56. Guilhot F, Apperley JF, Kim D-W, et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 2007;110:(Abstract 470).
57. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-2183.
58. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150. (Pubitemid 46890528)
59. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
60. Shah NP, Kasap C, WeierC, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-493.
61. Quintas-Cardama A, Kantarjian HM, Nicaise C, et al. Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL(R)): clinical features and management, including outcome after hematopoietic growth factor therapy. Blood 2006;108:(Abstract 2163).
62. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914.
63. Heuchel R, Berg A, Tallquist M, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-30 kinase signaling. Proc Natl Acad Sci USA 1999;96:11410-11415.
64. Quintas-Cardama A, Kantarjian H, Ravandi F, Burger J, Borthakur G, Cortes J. Bleeding diathesis in patients (pts) with chronic myelogenous leukemia receiving dasatinib therapy. Blood 2007;110:(Abstract 2958).
65. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Dasatinib-induced platelet dysfunction. Blood 2007;110: (Abstract 2941).
66. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
67. Manley PW, Mestan J, Cowan-Jacob S, et al. AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase. Proc Am Assoc Cancer Res 2005;46:1408 (Abstract 5985).
68. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551. (Pubitemid 43882350)
69. Kantarjian HM, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood 2007;110:(Abstract 735).
70. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112: (Abstract 3238).
71. le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP)with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112:(Abstract 3229).
72. Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 2007;110: (Abstract 1025).
73. Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph+ALL) who are resistant or intolerant to imatinib. Blood 2007;110: (Abstract 2815).
74. Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311-2315.
75. Quintas-Cardama A. Experimental non-ATP-competitive therapies for chronic myelogenous leukemia. Leukemia 2008;22:932-940. (Pubitemid 351689874)
76. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008;14:4392-4399.
77. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-11322.
78. Cortes J, Kantarjian HM, Kim D-W, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood 2008;112: (Abstract 1098).
79. Passerini CG, Pogliani EM, Baccarani M, et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL. Blood 2008;112:(Abstract 1101).
80. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ ABL mutants. J Clin Oncol 2009;27:469-471.
81. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106:3948-3954.
82. Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306-314.
83. Kantarjian HM, Cortes J, le Coutre P, et al. A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 2007;110:(Abstract 469).
84. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-854.
85. Katayama H, Brinkley WR, Sen S. The aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-464.
86. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-502.
87. Giles F, Cortes J, Bergstrom DA, et al. MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCRABL T315I mutant chronic myelogenous leukemia (CML). Blood 2006;108:(Abstract 163).
88. Shah NP, Kasap C, Paquette R, et al. Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228. Blood 2007;110: (Abstract 474).
89. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinibresistant BCR-ABL mutations including T315I. Blood 2008;111:4355-4364.
90. Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF- 1R/ aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 2008;112:(Abstract 3232).
91. Paquette RL, Shah NP, Sawyers CL, et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 2007;110:(Abstract 1030).
92. Balabanov S, Gontarewicz A, Keller G, et al. Combination therapy of small molecule inhibitor PHA-739358 and tyrosine kinase inhibitor imatinib yields synergistic antiproliferative effects and suppresses emergence of resistance of chronic myeloid leukemia in vitro. Blood 2008;112: (Abstract 3227).
93. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M. Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 1988;80:1095-1103.
94. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl) 1976; 2:263-272.
95. Harringtonine in Acute Leukemias. Clinical analysis of 31 cases. Chin Med J (Engl) 1977;3:319-324.
96. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-3326.
97. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.Mol Cancer Ther 2006;5:723-731.
98. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109:248-255.
99. Robin J-P, Dhai R, Dujardin G, Girodier L, Mevellec L, Poutot S. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931-2934.
100. Cortes J, Khoury HJ, Corm S, et al. Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib(IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation - results of an ongoing multicenter phase II study. Blood 2008;112: (Abstract 3239).